|Targeting gene expression to hypoxic tumor cells|
GU Dachs, AV PATTERsoN, JD Firth, PJ Ratcliffe, KMS Townsend, ...
Nature medicine 3 (5), 515-520, 1997
|Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix|
R Airley, J Loncaster, S Davidson, M Bromley, S Roberts, A Patterson, ...
Clinical cancer research 7 (4), 928-934, 2001
|Mapping of brain activity by automated volume analysis of immediate early genes|
N Renier, EL Adams, C Kirst, Z Wu, R Azevedo, J Kohl, AE Autry, L Kadiri, ...
Cell 165 (7), 1789-1802, 2016
|Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104|
AV Patterson, DM Ferry, SJ Edmunds, Y Gu, RS Singleton, K Patel, ...
Clinical Cancer Research 13 (13), 3922-3932, 2007
|Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302|
F Meng, JW Evans, D Bhupathi, M Banica, L Lan, G Lorente, JX Duan, ...
Molecular cancer therapeutics 11 (3), 740-751, 2012
|Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase|
AV Patterson, H Zhang, A Moghaddam, R Bicknell, DC Talbot, IJ Stratford, ...
British journal of cancer 72 (3), 669-675, 1995
|Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia|
CP Guise, AM Mowday, A Ashoorzadeh, R Yuan, WH Lin, DH Wu, ...
Chinese journal of cancer 33 (2), 80, 2014
|The views and practice of oncologists towards nutritional support in patients receiving chemotherapy|
A Spiro, C Baldwin, A Patterson, J Thomas, HJN Andreyev
British journal of cancer 95 (4), 431-434, 2006
|The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3|
CP Guise, MR Abbattista, RS Singleton, SD Holford, J Connolly, ...
Cancer research 70 (4), 1573-1584, 2010
|Structure− activity relationships of 1, 2, 4-benzotriazine 1, 4-dioxides as hypoxia-selective analogues of tirapazamine|
MP Hay, SA Gamage, MS Kovacs, FB Pruijn, RF Anderson, AV Patterson, ...
Journal of medicinal chemistry 46 (1), 169-182, 2003
|A critical evaluation of the relationship between serum vitamin B12, folate and total homocysteine with cognitive impairment in the elderly|
M Ellinson, J Thomas, A Patterson
Journal of human nutrition and dietetics 17 (4), 371-383, 2004
|Novel chimeric gene promoters responsive to hypoxia and ionizing radiation|
O Greco, B Marples, GU Dachs, KJ Williams, AV Patterson, SD Scott
Gene therapy 9 (20), 1403-1411, 2002
|Enzymology of tirapazamine metabolism: a review|
AV Patterson, MP Saunders, EC Chinje, LH Patterson, IJ Stratford
Anti-cancer drug design 13 (6), 541-573, 1998
|Bystander or no bystander for gene directed enzyme prodrug therapy|
GU Dachs, MA Hunt, S Syddall, DC Singleton, AV Patterson
Molecules 14 (11), 4517-4545, 2009
|Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954|
GA Prosser, JN Copp, SP Syddall, EM Williams, JB Smaill, WR Wilson, ...
Biochemical pharmacology 79 (5), 678-687, 2010
|Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233)|
AV Patterson, HM Barham, EC Chinje, GE Adams, AL Harris, IJ Stratford
British journal of cancer 72 (5), 1144-1150, 1995
|Overexpression of human NADPH: cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069|
AV Patterson, MP Saunders, EC Chinje, DC Talbot, AL Harris, IJ Strafford
British Journal of Cancer 76 (10), 1338-1347, 1997
|Cancer chemotherapy and drug metabolism|
DS Riddick, C Lee, S Ramji, EC Chinje, RL Cowen, KJ Williams, ...
Drug Metabolism and Disposition 33 (8), 1083-1096, 2005
|2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT|
NA Helsby, DM Ferry, AV Patterson, SM Pullen, WR Wilson
British journal of cancer 90 (5), 1084-1092, 2004
|Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH: cytochrome P450 oxidoreductase under hypoxia|
CP Guise, AT Wang, A Theil, DJ Bridewell, WR Wilson, AV Patterson
Biochemical pharmacology 74 (6), 810-820, 2007